PTC Therapeutics | PTCT - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amgen USD 4.78B 1.12B 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cytokinetics USD 200.58M 4.46M 2026-03
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
TG Therapeutics USD 170.12M 28.04M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Xencor USD 82.38M 513K 2026-03